Skip to main content

Harmony Biosciences Holdings, Inc. (HRMY)

NASDAQ: HRMY · IEX Real-Time Price · USD
36.79 -0.31 (-0.84%)
Sep 17, 2021 4:00 PM EDT - Market closed
Market Cap2.08B
Revenue (ttm)235.39M
Net Income (ttm)17.19M
Shares Out57.01M
EPS (ttm)0.34
PE Ratio108.85
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,972,255
Open37.31
Previous Close37.10
Day's Range36.02 - 37.31
52-Week Range25.09 - 52.74
Betan/a
AnalystsBuy
Price Target51.33 (+39.5%)
Est. Earnings DateNov 9, 2021

About HRMY

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvani...

IndustryBiotechnology
IPO DateAug 19, 2020
Employees150
Stock ExchangeNASDAQ
Ticker SymbolHRMY
Full Company Profile

Financial Performance

In 2020, HRMY's revenue was $159.74 million, an increase of 2,564.59% compared to the previous year's $6.00 million. Losses were -$36.94 million, -75.69% less than in 2019.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for HRMY stock is "Buy." The 12-month stock price forecast is 51.33, which is an increase of 39.52% from the latest price.

Price Target
$51.33
(39.52% upside)
Analyst Consensus: Buy

News

Harmony Biosciences To Participate In Three Investor Conferences In September

PLYMOUTH MEETING, Pa., Sept. 2, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therap...

2 weeks ago - PRNewsWire

Harmony Biosciences Stock Is Trading Higher On $330M Financing Deal With Blackstone, Q2 Earning Beat Estimates

Harmony Biosciences Holdings Inc (NASDAQ: HRMY) has entered into a $330 million financing collaboration with The Blackstone Group Inc (NYSE: BX). The financing deal includes up to $300 million in debt c...

1 month ago - Benzinga

Harmony Biosciences Reports Second Quarter 2021 Financial Results and Business Updates

WAKIX® (pitolisant) Net Revenue of $73.8 Million for Second Quarter 2021 vs. $38 Million for the Same Period in 2020

1 month ago - GlobeNewsWire

Harmony Biosciences And Blackstone Enter Into Strategic Financing Collaboration

PLYMOUTH MEETING, Pa. and NEW YORK, Aug. 10, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing inno...

Other symbols:BX
1 month ago - PRNewsWire

Harmony Biosciences Acquires Asset With Novel Mechanism Of Action For The Potential Treatment Of Narcolepsy And Other...

PLYMOUTH MEETING, Pa., Aug. 9, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapi...

1 month ago - PRNewsWire

John C. Jacobs, President And CEO Of Harmony Biosciences, Named An Ernst & Young (EY) Entrepreneur Of The Year 2021 G...

PLYMOUTH MEEETING, Pa., July 29, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative thera...

1 month ago - PRNewsWire

Harmony Biosciences Announces Date Of Second Quarter 2021 Financial Results

PLYMOUTH MEETING, Pa., July 27, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing ...

1 month ago - PRNewsWire

Harmony Biosciences Initiates A Phase 2 Clinical Trial In Myotonic Dystrophy

PLYMOUTH MEETING, Pa., June 29, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therap...

2 months ago - PRNewsWire

Harmony Biosciences Presents New Analysis Of Clinical Impact For WAKIX® (pitolisant) At The SLEEP 2021 Annual Meeting

PLYMOUTH MEETING, Pa., June 10, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therap...

3 months ago - PRNewsWire

Harmony Biosciences Announces Applications for 2021 Patients At The Heart Grant Program Open June 9

PLYMOUTH MEETING, Pa., June 9, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapi...

3 months ago - PRNewsWire

Harmony Biosciences To Present New Data Analyses For WAKIX® (pitolisant) At The SLEEP 2021 Annual Meeting

PLYMOUTH MEETING, Pa., June 7, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapi...

3 months ago - PRNewsWire

Harmony Biosciences to Participate in Three Investor Conferences in June

PLYMOUTH MEETING, Pa., May 26, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapi...

3 months ago - PRNewsWire

John C. Jacobs, President and CEO of Harmony Biosciences, Joins Life Sciences Pennsylvania Board of Directors

PLYMOUTH MEETING, Pa., May 18, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapi...

3 months ago - PRNewsWire

Harmony Biosciences to Present at the Oppenheimer Rare and Orphan Disease Summit

PLYMOUTH MEETING, Pa., May 18, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapi...

3 months ago - PRNewsWire

Harmony Biosciences Reports First Quarter 2021 Results and Business Updates

WAKIX® (pitolisant) Total Revenue of $59.7 Million for First Quarter 2021

4 months ago - GlobeNewsWire

Drug/Biotech Stock Q1 Earnings on May 10: CPRX, PRTA & More

Let us take a look at four small companies, CPRX, MYOV, PRTA, HRMY, which are gearing up for their earnings release.

Other symbols:CPRXMYOVPRTA
4 months ago - Zacks Investment Research

Harmony Biosciences To Present WAKIX® (pitolisant) Efficacy and Safety Data at Upcoming 2021 American Psychiatric Ass...

PLYMOUTH MEETING, Pa., April 27, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("the Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative t...

4 months ago - PRNewsWire

Harmony Biosciences To Present WAKIX® (Pitolisant) Data At The 2021 AAN Annual Meeting

PLYMOUTH MEETING, Pa., April 12, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative thera...

5 months ago - PRNewsWire

Harmony Biosciences Launches Grant Program To Address Inequities In The Delivery Of Healthcare In Patients With Sleep...

PLYMOUTH MEETING, Pa., April 7, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therap...

5 months ago - PRNewsWire

4 New Standout Stocks From Goldman Sachs Analysts

Analysts at Goldman Sachs are out with four new Buy recommendations on companies in the oil, biotech and health care businesses.

Other symbols:OVVOSCRINNV
5 months ago - 24/7 Wall Street

Harmony Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results and Business Updates

WAKIX® (pitolisant) Total Revenue of $160 Million for Full-Year 2020; $56 Million for Fourth Quarter 2020

5 months ago - GlobeNewsWire

Harmony Biosciences Hosts Summit Which Sheds Light on Impact of Sleep Disruption in Rare Diseases

PLYMOUTH MEETING, Pa., March 19, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative thera...

5 months ago - PRNewsWire

Harmony Biosciences Highlights Publication of WAKIX® (pitolisant) Efficacy Data in Sleep Medicine

PLYMOUTH MEETING, Pa., March 17, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative thera...

6 months ago - PRNewsWire

Harmony Biosciences Appoints Sandip Kapadia as Chief Financial Officer

PLYMOUTH MEETING, Pa., March 15, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative thera...

6 months ago - PRNewsWire

Harmony Biosciences Announces Date Of Fourth Quarter And Full Year 2020 Financial Results

PLYMOUTH MEETING, Pa., March 4, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therap...

6 months ago - PRNewsWire